Status: Recruiting
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib to find the best safe dose for further testing.
Participants needed: 54
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: May 22, 2026Locations: 7
Eligibility criteria
A diagnosis of unresectable, recurrent, or metastatic DDLPS [+25]
Patients who have not recovered from clinically significant adverse events of pr... [+21]